630421-48-6

Basic information

• Product Name: t-Butyl(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropylcarbamate
• Synonyms: t-Butyl(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropylcarbamate;tert-butyl (1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropylcarbamate;CarbaMic acid, N-[(1R,2S)-1-[[(cyclopropylsulfonyl)aMino]carbonyl]-2-ethenylcyclopropyl]-, 1,1-diMethylethyl ester;N-[(1R,2S)-1-[[(cyclopropylsulfonyl)aMino]carbonyl]-2-ethenylcyclopropyl]-, 1,1-diMethylethyl ester;[(1R,2S)-1-[[(Cyclopropylsulfonyl)amino]carbonyl]-2-ethenylcyclopropyl]carbamic acid 1,1-dimethylethyl ester;N-[(1R,2S)-1-[[(cyclopropylsulfonyl)amino]carbonyl]-2-ethenylcyclopropyl]carbamic acid 1,1-dimethylethyl ester;Asunaprevir Intermediate 1;tert-butyl N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinyl-cyclopropyl]carbamate
• CAS NO: 630421-48-6
• Molecular Formula: C₁₄H₂₂N₂O₅S
• Molecular Weight: 330.39988
• Product Categories: intermediates
• Mol File: 630421-48-6.mol
• Article Data: 27

Chemical Properties

• Appearance: /
• Density: 1.299 g/cm³
• Refractive Index: 1.547
• PKA: 4.68±0.40(Predicted)
• CAS DataBase Reference: t-Butyl(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: t-Butyl(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropylcarbamate(630421-48-6)
• EPA Substance Registry System: t-Butyl(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropylcarbamate(630421-48-6)

Safety Data

• Hazardous Substances Data: 630421-48-6(Hazardous Substances Data)

Usage

General Description

T-Butyl(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropylcarbamate is a chemical compound with the molecular formula C16H24N2O4S. It is a highly specific and selective inhibitor of serine protease prolyl oligopeptidase (POP). t-Butyl(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropylcarbamate is commonly used in biochemical and pharmacological research as a tool compound to study the functions and roles of POP in various biological processes. It has also been investigated for its potential therapeutic applications in the treatment of neurodegenerative diseases and psychiatric disorders. Additionally, it has shown promising results in preclinical studies for its ability to inhibit the growth of cancer cells by targeting POP. This chemical compound is an important tool in understanding the mechanisms and potential therapeutic targets in various diseases and disorders.

InChI:InChI=1/C14H22N2O5S/c1-5-9-8-14(9,15-12(18)21-13(2,3)4)11(17)16-22(19,20)10-6-7-10/h5,9-10H,1,6-8H2,2-4H3,(H,15,18)(H,16,17)/t9-,14-/m1/s1

Upstream product

• 154350-29-5 cyclopropanesulphonamide 
• 213316-49-5 (1RS,2SR)-ethyl 2-vinyl-1-(tert-butoxycarbonylamino)cyclopropanecarboxylate 
• 213316-32-6 rac-(1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid ethyl ester 
• 1023795-84-7 C₂₁H₂₁NO₂ 
• 681807-59-0 (1R,2S)-ethyl 1-(tert-butoxycarbonylamino)-2-vinylcyclopropanecarboxylate 
• 1393095-18-5 (E)-ethyl 1-(benzylideneamino)-2-vinylcyclopropanecarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 787548-29-2 (1R,2S)/(1S,2R) 1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 141-78-6 ethyl acetate 
• 259217-95-3 N-Boc-(1R,2S)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester 
• 159622-10-3 (1R,2S)-1-(tert-butoxycarbonylamino)-2-vinylcyclopropanecarboxylic acid 

Downstream Products

• 1275620-42-2 {4-cyclopropanesulfonylaminocarbonyl-2,15-dioxo-18-[2-(4-trifluoromethyl-phenyl)-benzo[4,5]furo[3,2-d]pyrimidin-4-yloxy]-3,16-diaza-tricyclo[14.3.0.0(4,6)]nonadec-7-en-14-yl}-carbamic acid cyclopentyl ester 
• 1275617-56-5 {4-cyclopropanesulfonylaminocarbonyl-2,15-dioxo-18-[2-(4-trifluoromethyl-phenyl)-benzo[4,5]furo[3,2-d]pyrimidin-4-yloxy]-3,16-diaza-tricyclo[14.3.0.0(4,6)]nonadec-14-yl}-carbamic acid cyclopentyl ester 
• 1028252-79-0 C₃₁H₃₁F₃N₄O₇S 
• 1028252-78-9 C₃₆H₃₉F₃N₄O₉S 
• 1028329-00-1 C₃₇H₄₂F₃N₅O₈S 
• 1028252-80-3 C₄₂H₅₀F₃N₅O₁₀S 
• 1029259-64-0 tert-butyl (S)-1-((2S,4S)-2-((1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropylcarbamoyl)-4-phenylpyrrolidin-1-yl)-1-oxonon-8-en-2-ylcarbamate 
• 1029259-55-9 C₃₂H₄₄N₄O₇S 
• 914662-37-6 (2S,4S)-N-((1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropyl)-4-phenylpyrrolidine-2-carboxamide hydrochloride 
• 630421-49-7 (1R,2S)-1-amino-N-(cyclopropylsulfonyl)-2-ethenylcyclopropanecarboxamide hydrochloride 
• 1001667-23-7 (2S,4R)-1-((S)-2-tert-butyl-4-oxo-4-(piperidin-1-yl)butanoyl)-N-((1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropyl)-4-(6-methoxy-3-phenylisoquinolin-1-yloxy)pyrrolidine-2-carboxamide 
• 905994-07-2 C₂₈H₃₅FN₄O₈S 
• 1195976-54-5 C₄₄H₄₇F₃N₆O₉S 
• 921790-46-7 C₃₂H₄₃BrN₄O₁₀S₂ 

Relevant articles and documents

Macrocyclic compounds for suppressing replication of hepatitis C virus

A compound as represented by Formula (I) is provided, wherein groups are defined in the description. The compound is used as HCV protease inhibitor for treating HCV infection.

MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS

A compound as represented by Formula (I) is provided, wherein groups are defined in the description. The compound is used as HCV protease inhibitor for treating HCV infection.

HCV NS3 PROTEASE INHIBITORS

The present invention is directed to compounds, compositions and methods for treating or preventing HCV viral infections in human patients or other animal hosts.